Endocrinologie

Diabète

Antidiabétique, INESS, nov 2019

Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials Palmer Suetonia C, Tendal Britta, Mustafa Reem A, Vandvik Per Olav, Li Sheyu, Hao Qiukui et al. BMJ 2021; 372 :m4573

Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Davies MJ, D'Alessio DA, Fradkin J, et al. Diabetes Care 2018;41(12):2669-2701.

Lignes directrices de pratique clinique 2013 de l'Association canadienne du diabète pour la prévention et le traitement du diabète au Canada, Can J Diabetes, October 2013, Volume 37, Supplement 5, S361-S598

Treatment of Type 1 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes JJ Chamberlain et al. Ann Intern Med. 2017 Sep 12

Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline update from the American College of Physicians. Ann Intern Med 2017;166(4):279-290. Clinical Guidelines Committee of the American College of Physicians.

Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. BMJ. 2017 Jun 8;357:j2499. doi: 10.1136/bmj.j2499.

Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Wittert G, Bracken K, Robledo KP, Grossmann M, Yeap BB, Handelsman DJ, Stuckey B, Conway A, Inder W, McLachlan R, Allan C, Jesudason D, Fui MNT, Hague W, Jenkins A, Daniel M, Gebski V, Keech A. Lancet Diabetes Endocrinol. 2021 Jan;9(1):32-45. doi: 10.1016/S2213-8587(20)30367-3. PMID: 33338415.